• Kenneth J. Clemetson
  • R. Manjunatha KiniEmail author


Haemostasis is critical to normal health by preventing blood loss following injury and contributing to the maintenance of the vasculatory system, which supplies oxygen and nutrients to all parts of the body as well as performing other essential tasks. Thrombosis is the pathological variant leading to blockage of vessels, cutting off the blood supply to vital organs. Because of these important functions there is great interest in the development of new drugs that can prevent or cure thrombosis. Since platelet malfunction is a major contributor to thrombus formation and platelet inhibition reduces risk it is a prime target for new drug development. Many animals have developed naturally proteins or peptides that affect mammalian haemostasis. They use these mechanisms either to immobilise or kill prey in the case of snakes or to enhance blood feeding in the case of haematophagous insects or vampire bats. Often these proteins are effective in extremely small amounts. This book provides descriptions of a number of different classes of such proteins from snakes and insects and their target molecules on platelets, as a way of developing new approaches to anti-thrombotic drugs.


Platelet Aggregation Snake Venom Section Deal Pyroglutamic Acid Venom Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bell, W.R.J., 1997. Defibrinogenating enzymes. Drugs 54 (Suppl. 3), 18–30.PubMedCrossRefGoogle Scholar
  2. Brunner, H.R., Gavras, H., Turini, G.A., Waeber, B., Cappuis, P., McKinstry, D.N., 1978. Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. Clin. Sci. Mol. Med. Suppl. 4, 293 s–295 s.PubMedGoogle Scholar
  3. Ferreira, S.H., Rocha e Silva, M., 1965. Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom. Experientia 21, 347–349.PubMedCrossRefGoogle Scholar
  4. Fry, B.G., Vidal, N., Norman, J.A., Vonk, F.J., Scheib, H., Ramjan, S.F., Kuruppu, S., Fung, K., Hedges, S.B., Richardson, M.K., Hodgson, W.C., Ignjatovic, V., Summerhayes, R., Kochva, E., 2006. Early evolution of the venom system in lizards and snakes. Nature 439, 584–588.PubMedCrossRefGoogle Scholar
  5. Fry, B.G., Wroe, S., Teeuwisse, W., van Osch, M.J., Moreno, K., Ingle, J., McHenry, C., Ferrara, T., Clausen, P., Scheib, H., Winter, K.L., Greisman, L., Roelants, K., van der Weerd, L., Clemente, C.J., Giannakis, E., Hodgson, W.C., Luz, S., Martelli, P., Krishnasamy, K., Kochva, E., Kwok, H.F., Scanlon, D., Karas, J., Citron, D.M., Goldstein, E.J., McNaughtan, J.E., Norman, J.A., 2009. A central role for venom in predation by Varanus komodoensis (Komodo Dragon) and the extinct giant Varanus (Megalania) priscus. Proc. Natl. Acad. Sci., U.S.A. 106, 8969–8974.PubMedCrossRefGoogle Scholar
  6. Hantgan, R.R., Stahle, M.C., 2009. Integrin priming dynamics: mechanisms of integrin antagonist-promoted αIIbβ3:PAC-1 molecular recognition. Biochemistry 48, 8355–8365.PubMedCrossRefGoogle Scholar
  7. Hartman, G.D., Egbertson, M.S., Halczenko, W., Laswell, W.L., Duggan, M.E., Smith, R.L., Naylor, A.M., Manno, P.D., Lynch, R.J., Zhang, G.X., Chang, C.T.C., Gould, R.J., 1992. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35, 4640–4642.PubMedCrossRefGoogle Scholar
  8. Kaplan, H.R., Cohen, D.M., Essenburg, A.D., Major, T.C., Mertz, T.E., Ryan, M.J., 1984. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors. Fed. Proc. 43, 1326–1329.PubMedGoogle Scholar
  9. Mousa, S.A., Kapil, R., Mu, D.X., 1999. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler. Thromb. Vasc. Biol. 19, 2535–2541.PubMedCrossRefGoogle Scholar
  10. Ofosu, F.A., Fenton, J.W., II., Maraganore, J., Blajchman, M.A., Yang, X., Smith, L., Anvari, N., Buchanan, M.R., Hirsh, J., 1992. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. Biochem. J. 283, 893–897.PubMedGoogle Scholar
  11. Römisch, J., Stöhr, H.A., Stauss, H., Koschinsky, R., Stüber, W., Pâques, E.P., 1994. Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide. Thromb. Haemost. 71, 320–324.PubMedGoogle Scholar
  12. Scarborough, R.M., Rose, J.W., Hsu, M.A., Phillips, D.R., Fried, V.A., Campbell, A.M., Nannizzi, L., Charo, I.F., 1991. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. 266, 9359–9362.PubMedGoogle Scholar
  13. Schoni, R., 2005. The use of snake venom-derived compounds for new functional diagnostic test kits in the field of haemostasis. Pathophysiol. Haemost. Thromb. 34, 234–240.PubMedCrossRefGoogle Scholar
  14. Sweet, C.S., Gross, D.M., Arbegast, P.T., Gaul, S.L., Britt, P.M., Ludden, C.T., Weitz, D., Stone, C.A., 1981. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J. Pharmacol. Exp. Ther. 216, 558–566.PubMedGoogle Scholar
  15. Tcheng, J.E., Harrington, R.A., Kottke-Marchant, K., Kleiman, N.S., Ellis, S.G., Kereiakes, D.J., Mick, M.J., Navetta, F.I., Smith, J.E., Worley, S.J., Miller, J.A., Joseph, D.M., Sigmon, K.N., Kitt, M.M., Dumee, C.P., Califf, R.M., Topol, E.J., 1995. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 91, 2151–2157.CrossRefGoogle Scholar
  16. Tschudi, M., Lämmle, B., Alberio, L., 2009. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood 113, 2402–2409.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Department of HaematologyUniversity of BerneBerneSwitzerland
  2. 2.Protein Science Laboratory, Department of Biological SciencesNational University of SingaporeSingaporeSingapore
  3. 3.Department of Biochemistry and Molecular BiophysicsMedical College of Virginia, Virginia Commonwealth UniversityRichmondUSA

Personalised recommendations